Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Across all dose levels, only 1 DLT and no G 4/5 AEs in this phase 1b trial of the IDO1 inhibitor GDC-0919+the PD-L1 targeting atezolizumab (Tecentriq).
Why this matters
Combination generally well tolerated.
Demonstrated peripheral IDO1 modulation and preliminary efficacy during dose escalation.
Study enrolling more patients in expansion cohorts to assess tumor PD and combination efficacy.
Interventional phase 1b open-label dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GDC-0919+atezolizumab in patients with locally advanced or metastatic solid tumors.
Escalating doses of GDC-0919 (50-1000 mg orally twice daily for 21 d) and atezolizumab (1200 mg intravenously every 3 wk) in standard 3+3 design.
Funding: Genentech, Inc.
At December 14, 2016, 52 patients had been treated in 6 co...